ThermoGenesis Holdings Inc (THMO)
0.65
-0.04
(-5.80%)
USD |
NASDAQ |
Apr 24, 16:00
0.65
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 5.169M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -62.69% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.1695 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -4.593 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.99% |
Profile
| ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications. |
| URL | https://www.thermogenesis.com |
| Investor Relations URL | https://thermogenesis.com/investors/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Small Cap/Value |
| Next Earnings Release | N/A |
| Last Earnings Release | Aug. 12, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications. |
| URL | https://www.thermogenesis.com |
| Investor Relations URL | https://thermogenesis.com/investors/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Small Cap/Value |
| Next Earnings Release | N/A |
| Last Earnings Release | Aug. 12, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |